The World’s First Thin Strut Sirolimus to Treat Stent Thrombosis in Coronary Artery Disease

MeRes100 BRS, the world’s first thin strut sirolimus-eluting bioresorbable vascular scaffold shows very long-term positive safety with consistency low MACE rates and efficacy outcomes for patients with coronary artery disease.


A study on MeRes-1 for a long term of three years was published in Eurointervention, demonstrated with high efficacy of MeRes100 with multimodality imaging in two years including:

Low late lumen loss (0.24±0.34mm) with quantitative coronary angiography (QCA)

Virtually complete strut coverage (99.24%) with optical coherence tomography (OCT)

Sustained mean flow area and very low percentage volume obstruction (7.5%) with intravascular ultrasound (IVUS)

MeRes-1 Extend

Two-year data from the global study on patients from Brazil, Europe and Asia, demonstrated low late lumen loss (0.18±0.31mm) with a serial QCA analysis at six-month observation.

Suggesting high efficacy on inhibiting NIH at late follow-up, and a sustained mean flow area and virtually complete strut coverage (97.9±3.7) shown in an OCT subset analysis at six months.

MeRes100 BRS

MeRes100 BRS is a product designed and manufactured in India by Meril Life Sciences.

MeRes100 BRS is a bioresorbable vascular scaffold system with low strut thickness of 100microns that fully resorbs naturally in the artery within a period of 2-3 years, leaving the vessel in its true form and nature.